Growth of nervous tissue in the regenerated rabbit ear chamber.

J. Falk,K. Arfors,F. Mckenzie

DOI: https://doi.org/10.3109/03009737309178623

Upsala Journal of Medical Sciences

Abstract:Highly specific nerve staining using thiocholine techniques has been applied to a study of nerve regeneration in titanium rabbit ear chambers. Early and extensive ingrowth of nerves rich in true cholinesterase activity was demonstrated.

What problem does this paper attempt to address?

Prognostic Significance of Huntingtin Interacting Protein 1 Expression on Patients with Acute Myeloid Leukemia

Jinghan Wang,Mengxia Yu,Qi Guo,Qiuling Ma,Chao Hu,Zhixin Ma,Xiufeng Yin,Xia Li,Yungui Wang,Hanzhang Pan,Dongmei Wang,Jiansong Huang,Haitao Meng,Hongyan Tong,Wenbin Qian,Jie Jin

DOI: https://doi.org/10.1038/srep45960

IF: 4.6

2017-01-01

Scientific Reports

Abstract:Huntingtin interacting protein 1 (HIP1) is an endocytic protein which is overexpressed in a variety of human cancers and involved in cancer-causing translocation in leukemia. However, the prognostic impact of HIP1 expression on AML remains unclear. In this study, quantification of HIP1 transcript by real-time quantitative PCR in bone marrow blasts was performed in 270 AML patients. As a result, high HIP1 expression was seen more frequently in older patients, M4/M5 morphology and genes of NPM1 and DNMT3A mutations, and underrepresented in favorable karyotype subgroups and CEBPA double allele mutations in our AML patients. We also found high HIP1 expressers showed lower levels of hemoglobin. In addition, overexpression of HIP1 was associated with an inferior overall survival. The prognostic value of HIP1 expression was validated in patients from an independent TCGA cohort. Notably, up-regulation of miR-16, miR-15a, miR-28 and miR-660 were seen in high HIP1 expressers from the two independent cohorts. In vitro, interfereing of HIP1 expression by siRNA suppressed the proliferation of leukemic cells, and downregulation of these miRNAs were seen in THP-1 and Kasumi cell lines after silencing HIP1 expression. In conclusion, the HIP1 gene expression might serve as a reliable predictor for overall survival in AML patients.
Expression and Clinical Significance of ID1 Gene in Acute Myeloid Leukemia

Ying Lu,Qiong Wang,Qi-tian Mu,Zhi-mei Chen,Ji-yu Lou,Wan-mao Ni,Jie Jin

DOI: https://doi.org/10.3760/cma.j.issn.0253-2727.2012.04.006

2012-01-01

Abstract:OBJECTIVE:To explore the expression and clinical significance of ID1 gene in acute myeloid leukemia (AML) patients.METHOD:Real-time quantitative PCR (RQ-PCR) was used to test the expression level of ID1 gene in 114 de novo adult AML patients, and the clinical features of these patients were analyzed.RESULTS:ID1 gene transcript levels were detectable in BM mononuclear cells from 114 patients with AML, the median expression level of all samples was 8525 (range: 57 - 11 233 238). There was a statistically significant difference on expression level of ID1 gene among the three different cytogenetic prognosis groups, and the poor prognosis group (median: 36 840, range: 336 - 11 233 238) harbored the significantly higher level of ID1 gene than the intermediate prognosis group (Median: 6630, range: 66 - 1 840 798) (P = 0.006). The expression level of ID1 gene was positively associated with older age (age ≥ 60 years vs < 60 years, P = 0.002) and higher WBC count (WBC ≥ 10×10(9)/L vs < 10×10(9)/L, P = 0.005). Young patients (age < 60 years) who were not obtained the complete remission (non-CR) after the first cycle of chemotherapy harbored the high level of ID1 gene (Median: 9537 of non-CR vs 1268 of CR, P = 0.010).CONCLUSIONS:High expression level of ID1 gene was mostly seen in AML patients with adverse cytogenetics and older age (age ≥ 60 years), and may be associated with poor prognosis of AML. ID1 gene might be a prognostic molecular marker of AML.
Expression Characteristics and Prognosissignificance of Mirna-181A in Acute Myeloid Leukemia with Normal Karyotype

X,Q L Ma,H P Wang,M X Yu,X Li,H T Meng,W J Yu,C J Jin,L S You,J Jin

DOI: https://doi.org/10.3760/cma.j.issn.0253-2727.2017.10.007

2017-01-01

Abstract:Objective: To study the expression of miRNA-181a in acute myeloid leukemia (AML) patients with normal karyotype to probe its prognosis significance. Methods: The expression level of miRNA-181a in bone marrow mononuclear cells of 120 de novo AML patients with normal karyotype was detected by real time fluorescence quantitative PCR. The direct sequencing method was used to detect IDH1, IDH2, NPM1, FLT3-ITD, DNMT3A and CEBPα mutations in CN-AML patients after PCR. The relationship between miRNA-181a expression and gene mutation, the clinical parameters and prognosis were analyzed. Results: The rates of overall surviva1 (OS) in high expression and low expression groups were 25.0 months and 15.0 months, respectively (P<0.05) . Relapse free survival (RFS) in high expression and low expression groups were 21.4 months and 11.2 months, respectively (P<0.05) . Significantly higher level hemoglobin, complete remission rate and proportion of wild type NPM1 expression in the high expression of miRNA-181a group were observed when compared with the lower expression of miRNA-181a group (P<0.05) . Multivariate Cox regression analysis showed miRNA-181a overexpression was an independent prognostic factor for CN-AML (HR=2.219, 95%CI 1.601~2.432, P=0.018) . Conclusion: Higher expression of miRNA-181a was a good prognostic factor independent of clinical parameters and high frequency gene mutations, which implicated that the miRNA-181a expression level could be used as an important prognostic indicator of AML patients with normal karyotype.
Prognostic Impact of MYH9 Expression on Patients with Acute Myeloid Leukemia

Mengxia Yu,Jinghan Wang,Zhijuan Zhu,Chao Hu,Qiuling Ma,Xia Li,Xiufeng Yin,Jiansong Huang,Ting Zhang,Zhixin Ma,Yile Zhou,Chenying Li,Feifei Chen,Jian Chen,Yungui Wang,Hanzhang Pan,Dongmei Wang,Jie Jin

DOI: https://doi.org/10.18632/oncotarget.10613

2016-01-01

Oncotarget

Abstract:MYH9 expression has previously been demonstrated as an independent predictor of clinical outcome in solid tumors. However, the prognostic relevance of MYH9 expression in acute myeloid leukemia is still unclear. Here, we found high MYH9 expressers were seen more frequently in females and more frequently in M4 morphology. We also found high MYH9 expressers had lower percentage of bone marrow blasts. In addition, overexpression of MYH9 was associated with an inferior overall survival. Notably, distinct microRNA signatures were seen in high MYH9 expressers. These results were also validated in an independent cohort of AML patients using the published data. In conclusion, gene of MYH9 expression might serve as a reliable predictor for overall survival in AML patients.
High IDH1 Expression is Associated with a Poor Prognosis in Cytogenetically Normal Acute Myeloid Leukemia.

Qiu-Ling Ma,Jing-Han Wang,Yun-gui Wang,Chao Hu,Qi-Tian Mu,Meng-Xia Yu,Lei Wang,Dong-Mei Wang,Min Yang,Xiu-Feng Yin,Fei-Fei Chen,Sha-Sha Lu,Jian Chen,Zhi-Juan Zhu,Sai-Juan Chen,Jie Jin

DOI: https://doi.org/10.1002/ijc.29395

2015-01-01

International Journal of Cancer

Abstract:The prognostic value of IDH1 mutations has been systematically evaluated in acute myeloid leukemia (AML) patients recently. However, the role of IDH1 expression in AML is still under exploration. To investigate the clinical significance, we analyzed the IDH1/2 expression in 320 patients with cytogenetically normal AML (CN‐AML) by quantitative real‐time reverse‐transcription polymerase chain reaction. High expression of IDH1 was predominant in patients with FLT3‐ITD and DNMT3A mutations and less prevalent in cases with CEBPA double allele mutations. Strong association was observed between high IDH1 expression and low expression of microRNA 181 family. Prognosis was adversely affected by high IDH1 expression, with shorter overall survival and event‐free survival in the context of clinical characteristics, including age, WBC count, and gene mutations of NPM1, FLT3‐ITD, CEBPA, IDH1, IDH2 and DNMT3A in CN‐AML. Moreover, the clinical outcome of IDH1 expression in terms of overall survival, event‐free survival and complete remission rate still remained in multivariate models in CN‐AML. Importantly, the prognostic value was validated using the published microarray data from 79 adult patients treated according to the German AMLCG‐1999 protocol. Our results demonstrated that high IDH1 expression is associated with a poor prognosis of CN‐AML.
Plasma exosome-derived microRNA-532 as a novel predictor for acute myeloid leukemia

Xia Lin,Qing Ling,Yunfei Lv,Wenle Ye,Jiansong Huang,Xia Li,Qi Guo,Jinghan Wang,Zhongqi Li,Jie JIn

DOI: https://doi.org/10.3233/CBM-191164

2020-01-01

Cancer Biomarkers

Abstract:BACKGROUND: The interest in plasma biomarkers has increased recently. Plasma exosome-derived microRNA-532 is aberrantly expressed in a variety of human cancers and has the prognostic value in many solid tumors. However, the prognostic impact of the expression value on AML remains unclear. OBJECTIVE: The aim of this study is to investigate the prognostic value of exosome-derived microRNA-532 in AML patients. METHODS: We performed the real-time PCR to quantify exosome-derived microRNA-532 in plasma of 198 AML patients. To assess the prognostic value, we performed Cox regression analyses in the context of well-established clinical and molecular markers. Cellular metabolic profile was conducted to help us understand the biological insight of its expression. RESULTS: The expression level was not associated with white blood cell counts, age, FAB subtypes, cytogenetic risk groups and genes of FLT3-ITD, NPM1, CEBPA and DNMT3A mutations. Interestingly, high expressers had a favorable overall survival in the univariate analysis. This prognostic value was testified in the multivariate analysis. Moreover, up-regulation of miR-532 was negatively associated with cellular energy like fructose and glutamine. CONCLUSION: We found plasma exosome-derived microRNA-532 can be used as a novel survival predictor for acute myeloid leukemia.
Expression of BCL2L12 gene in de novo acute myeloid leukemia and its clinical implications]

Meng-xia Yu,Ying Lu,Qi-tian Mu,Qiong Wang,Zhi-mei Chen,Ji-yu Lou,Jie Jin

DOI: https://doi.org/10.3760/cma.j.issn.1003-9406.2013.05.008

2013-01-01

Abstract:To explore the expression of BCL2L12 gene and its clinical significance for de novo acute myeloid leukemia (AML).Real-time quantitative PCR (RQ-PCR) was employed to measure the expression of BCL2L12 gene in 134 patients with de novo AML. The results were correlated with clinical features of patients.BCL2L12 gene transcript was determined for 134 AML patients and 49 healthy controls, with the median levels measured 0.1029 (0.0119-26.4090) and 0.2677 (0.0173-1.2858), respectively. There was a significant difference in the strength of BCL2L12 gene expression between patients and normal controls (P < 0.01). Those with lower BCL2L12 expression levels had a higher FLT3-ITD mutation rate compared with those with higher levels (27% vs. 5%, P = 0.036). Relapsed or refractory AML patients had lower expression compared with newly diagnosed patients (0.0873 vs. 0.1359, P = 0.014). There was no difference in overall survival (OS) between patients with higher and lower expression levels. However, for AML patients with a normal karyotype, the OS for those with lower expression was significant shorter (P = 0.037).De novo AML patients have a lower level of BCL2L12 gene expression. AML patients with lower BCL2L12 expression have a higher FLT3-ITD mutation rate, and most of them are relapse or refractory patients. In addition, among patients with a normal karyotype, those with a lower BCL2L12 expression have a shorter OS. Therefore, expression of the BCL2L12 gene may be used as a prognostic marker for AML patients with a normal karyotype.
The Expression of LEF1 Gene and Its Clinical Significance in Chinese Patients with Acute Myeloid Leukemia

Yuan Fu,Huayuan Zhu,Wei Wu,Jiadai Xu,Wenyi Shen,Wei Xu,Peng Liu,Jianyong Li

DOI: https://doi.org/10.1182/blood.v120.21.4621.4621

IF: 20.3

2012-01-01

Blood

Abstract:Abstract Abstract 4621 Objective: Canonical Wnt signaling controls embryonic development, regulates cell growth, transference and differentiation, it also involves in the self-renewal process of normal tissue and multiplication of stem cell. Recently, the aberrant activation of the Wnt signaling pathway has been implicated in the pathogenesis of human neoplasm including leukemia. LEF1, as a major transcriptional factor of Wnt signaling, plays a pivotal role in lymphoid differentiation as well as in granulopoiesis. High expression of LEF1 has been proposed to be a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia (AML). In this study, we firstly investigated the expression level of LEF1 mRNA and its clinical significance in Chinese AML. Methods: 87 samples from 81 Chinese AML patients (81 primary untreated samples and 6 samples after induction therapy) and 14 healthy controls were collected in this study. The LEF1 mRNA expressions were measured by real-time PCR with fluorescent dye SYBR Green I, the GAPDH was used as internal control. The relative quantitative value of LEF1 expression was calculated by means of 2 (−ΔCt). We analyzed the results with established AML prognostic factors such as karyotype, gene mutations, fusion proteins, relapse-free survival (RFS) and overall survival (OS). Results: The expression level of LEF1 mRNA in 81 AML patients was significantly higher than 14 normal controls (p <0.001). LEF1 expression level was further analyzed in the subgroups distinguished by clinical characters. According to national comprehension cancer network (NCCN) guideline, we found that LEF1 was dramatically increased in patients with better risk karyotype group (n=18) than those with the intermediate risk karyotype group (n=51) (P=0.031); patients with PML-RARα positive (n=16) and AML1-ETO positive (n=5) have higher LEF1 level compared with those without PML-RARα or AML1-ETO (n=60). Among 70 patients who have received the induction therapy, we discovered that patients with relative higher LEF1 expression were more likely to achieve CR after first induction therapy (p= 0.031; CR: n=44, no CR: n=26); we further analyzed the samples before and after treatment from 6 patients who achieved CR, the results showed that the LEF1 level were dramatically decreased after first induction therapy (p=0.028). We can not find the differences in RFS and OS between low LEF1 expression group and high LEF1 expression group in total patients. However, among the AML patients with intermediate risk cytogenetic, the lower LEF1 expression was associated with worse RFS (median, 15.0 vs 31.7 months, P=0.044) and OS (median, 16.7 vs 33.7 months, P=0.046) compared with the higher LEF1 expression. Conclusion: These results showed the LEF1 expression in AML patients is markedly higher than normal controls, especially in patients with favorable risk karyotype and PML-RARα or AML1-ETO positive. Patients with higher LEF1 expression seems to more likely to achieve CR after induction therapy. Survival analysis revealed that the higher LEF1 expression patients have a significantly prolonged RFS and OS compared to the lower LEF1 expression patients in intermediate risk karyotype group of AML. Our results in Chinese patients verified that LEF1 can be a potential favorable marker in AML patients. Disclosures: No relevant conflicts of interest to declare.
Clinical significance of lymphoid enhancer-binding factor 1 expression in acute myeloid leukemia

Yuan Fu,Huayuan Zhu,Wei Wu,Jiadai Xu,Tingmei Chen,Bei Xu,Sixuan Qian,Jianyong Li,Peng Liu

DOI: https://doi.org/10.3109/10428194.2013.805759

2013-07-08

Abstract:Lymphoid enhancer-binding factor 1 (LEF1) is a downstream effector of the Wnt/β-catenin signaling pathway and its dysregulation is associated with a number of malignant diseases such as leukemia. We explored the expression profile of LEF1 in acute myeloid leukemia (AML) and determined its specific prognostic significance in this disease. The LEF1 mRNA level in patients with previously untreated AML was significantly higher than in normal controls. Patients with AML with relatively higher LEF1 expression were more likely to achieve a complete remission (CR) following induction therapy in comparison to those with a lower LEF1 level. Moreover, we provide the first evidence that primary AML samples with AML1-ETO or PML-RARα have a higher LEF1 level compared with those without each fusion gene. High LEF1 expression predicts a significantly better overall survival for patients with intermediate-risk cytogenetics. High LEF1 level was associated with a favorable relapse-free survival in patients with FLT3-ITD wild-type. Finally, a scoring system based on LEF1 level and mutation status of FLT3-ITD or NPM1 is reliable to predict the outcome for AML with intermediate-risk cytogenetics. Our results indicate that LEF1 contributes to the pathophysiology of AML and could serve as a novel predictor of better treatment response. LEF1 level may be incorporated into an improved risk classification system for certain specific subtypes of AML.

oncology,hematology
[Expression of lncRNA UCA1 in Acute Myeloid Leukemia Patients and Its Clinical Significance]

Xue Bai,Yan-Ping Wu,Zhong-Yu Li,Xiao-Feng Chen,Meng Wang,Jia-Jia Li

DOI: https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.04.004

Abstract:Objective: To investigate the expression level of urothelial carcinoembryonic antigen 1 (lncRNA UCA1) in the bone marrow of acute myeloid leukemia (AML) patients, and to explore the clinical significance of lncRNA UCA1 expression level in AML patients. Methods: Bone marrow samples of 50 AML patients were collected as experimental group, and bone marrow samples of 20 iron deficiency anemia (IDA) patients were collected as control group. The relevant clinicopathological characteristics of AML patients were collected. Real-time quantitative PCR (qRT-PCR) was used to detect the expression level of lncRNA UCA1 in the experimental and control groups, and the relationships between lncRNA UCA1 expression and clinical pathological characteristics and prognosis in AML patients were analyzed. Kaplan-Meier curves were used to analyze the effect of lncRNA UCA1 on the overall survival (OS) of AML patients; And Cox regression model was used to analyze the factors affecting the prognosis of AML patients. Results: Compared with the control group, the expression level of lncRNA UCA1 was significantly elevated in patients with AML (P < 0.001); The proportion of patients with hemoglobin lower than 90 g/L in lncRNA UCA1 high expression group was significantly higher than that in lncRNA UCA1 low expression group (P =0.004); The expression level of lncRNA UCA1 was higher in M1, M2, and M4 subtypes, while it was lower in M0 and M5 subtypes, and the difference was statistically significant (P =0.009). There were no significant difference in sex, age, white blood cell (WBC) count, platelet (PLT) count, bone marrow blasts , chemotherapy regimen and efficacy, karyotype, gene mutation, and prognostic risk stratification between patients in UCA1 high expression group and those in UCA1 low expression group (all P > 0.05). The OS of patients with high expression of lncRNA UCA1 was significantly shorter than that of patients with low expression of lncRNA UCA1 (P =0.0229). Conclusion: The expression level of lncRNA UCA1 is significantly upregulated in AML patients. High expression of lncRNA UCA1 is associated with poor clinicopathological features and poor prognosis. Therefore, lncRNA UCA1 can be used as a prognostic indicator and a potential therapeutic target for AML patients.
High Expression of lncRNA HEIH is Helpful in the Diagnosis of Non-Small Cell Lung Cancer and Predicts Poor Prognosis

Chaowen He,Dongxuan Huang,Fan Yang,Dongsheng Huang,Yahui Cao,Jianfeng Peng,Xiaohua Luo

DOI: https://doi.org/10.2147/CMAR.S320965

2022-02-09

Cancer Management and Research

Abstract:Chaowen He, Dongxuan Huang, Fan Yang, Dongsheng Huang, Yahui Cao, Jianfeng Peng, Xiaohua Luo Department of Pulmonary and Critical Care Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, 518110, Guangdong, People's Republic of China Correspondence: Chaowen He, Department of Pulmonary and Critical Care Medicine, Shenzhen Longhua District Central Hospital, No. 187 Guanlan Avenue, Longhua District, Shenzhen, 518110, Guangdong, People's Republic of China, Tel +86-18123964996, Email Background: This study aims to investigate the expression and clinical value of long non-coding RNA (lncRNA) HEIH in peripheral blood of patients with non-small cell lung cancer (NSCLC). Methods: Healthy subjects (N=70), patients with lung squamous cell carcinoma (LUSC, N=70) and patients with lung adenocarcinoma (LUAD, N=80) were included. LncRNA HEIH expression in peripheral blood of included subjects was detected using RT-qPCR. According to the median expression of lncRNA HEIH, LUSC and LUAD patients were allocated into lncRNA HEIH high/low expression groups. The correlation between lncRNA HEIH and clinical indicators of patients was analyzed; Logistic multifactor regression was used to analyze the independent risk factors influencing lncRNA HEIH level. Receiver-operating characteristic (ROC) curve was used to evaluate the diagnostic efficacy of lncRNA HEIH and carcinoembryonic antigen (CEA) in LUSC/LUAD patients. MedCalc-Comparison of ROC curves was used to compare the area under ROC curve. The cumulative survival rates of lncRNA HEIH high/low expression group were analyzed by Kaplan–Meier curve. COX multivariate analysis was used to assess the independent factors affecting prognosis of NSCLC. Results: LncRNA HEIH in peripheral blood of LUSC/LUAD patients was higher than that in healthy controls, with no evident difference between LUSC and LUAD groups. In LUSC/LUAD patients, TNM stage, lymph node metastasis, distal metastasis, and CEA were independent risk factors affecting lncRNA HEIH; patients with high lncRNA HEIH expression had larger pack-years and tumor size, higher CEA level and tumor stage, and higher risk of lymph node metastasis and distal metastasis. LncRNA HEIH had higher diagnostic efficiency than CEA in NSCLC patients. High expression of lncRNA HEIH predicted poor prognosis in patients with NSCLC and was an independent risk factor for prognosis of NSCLC. Conclusion: High expression of lncRNA HEIH is helpful in the diagnosis of NSCLC and predicts poor prognosis. Keywords: non-small cell lung cancer, long non-coding RNA HEIH, prognosis, carcinoembryonic antigen, lung squamous cell carcinoma, lung adenocarcinoma, peripheral blood According to the data from China Cancer Registry Center, the incidence and mortality of lung cancer rank the first among malignant tumors in the world, 1 and about 2 million patients die of lung cancer every year, 2 among which non-small cell lung cancer (NSCLC) accounted for 80%~85%. 3 NSCLC can be divided into lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUCC) and large cell carcinoma (LCC) according to its pathological features. LUAD and LUSC accounted for approximately 50% and 40% of NSCLC patients, respectively. 4 LUAD is more common in women and smokers and is the main pathological subtype of lung tumors; there are no special symptoms in the early stage, mainly manifesting as respiratory diseases, including cough, low fever, and chest pain. 5,6 LUSC is more common in older men and has historically been strongly associated with smoking, and the main symptoms are fever, cough, hemoptysis, and chest pain. 7 In addition, genes in LUSC and LUAD patients were expressed differently. 8 For example, the diagnostic marker CEP55 was significantly differentially expressed in LUSC and LUAD. 9 Due to the atypical early clinical manifestations of the disease and the lack of biological markers for early diagnosis, about 75% of the patients were already in the middle and advanced stage when detected, and the tumor cells had lymphatic metastasis and distant metastasis, thus losing the best opportunity for surgical treatment and resulting in poor prognosis. 10 Therefore, it is of great significance to study the mechanism of the occurrence and development of NSCLC and to obtain novel biomarkers that can be used for early diagnosis, prognosis evaluation and treatment of NSCLC. Long non-coding RNA (lncRNA) is a class of RNA molecules with a transcript length of more than 200 nt without coding protein function, which can regulate gene expression level, post-transcriptional modification, binding to transcription factors or miRNAs, and play a regulatory role in many biological processes. 11 A study has -Abstract Truncated-

oncology
[New Advane of Reaserch on Relationship between Long Noncoding RNA and Acute Myeloid Leukemia--Review]

Zhang Fang,Zhe Yang,Ming-Ming Zhu,Duo-Nan Yu

DOI: https://doi.org/10.19746/j.cnki.issn.1009-2137.2020.04.057

Abstract:Acute myeloid leukemia（AML）is a myelopoietic stem/progenitor malignant disease. The exact etiology of this leukemia remains unclear, thus it is important to explore the pathogenesis of AML and to discover the new diagnostic markers and therapeutic targets. The long non coding RNA (lnc RNA) is a class of RNA molecules with transcripts over 200 nucleotides in eukaryotic cells which almost don't possess the ability to code proteins, but can regulate the expression of other genes at transcriptional and post-transcriptional levels, thereby participate in occurrence and development of varied tumors. Of late years, along with the deepening of study, the lncRNA roles played in the AML have been reported and confirmed. In this review, the relationships between the IncRNA (UCA1, ANRIL, H19, HOTAIR, CCAT1, ZFAS1, LINC00152, HOXA-A52, NEAT1, TUG1, IRAIN1, PANDAR, LINC00899, SNHG5, and KCNQ1OT1) and AML is summarized briefly, so as to provide the potential basis for the clinical diagnosis and therapy of AML.
High Expression of CLEC11A Predicts Favorable Prognosis in Acute Myeloid Leukemia

Chengliang Yin,Junyan Zhang,Wei Guan,Liping Dou,Yuchen Liu,Ming Shen,Xiaodong Jia,Lu Xu,Rilige Wu,Yan Li

DOI: https://doi.org/10.3389/fonc.2021.608932

IF: 4.7

2021-03-02

Frontiers in Oncology

Abstract:Background Acute myeloid leukemia (AML) is a heterogeneous disease of the hematopoietic system, for which identification of novel molecular markers is potentially important for clinical prognosis and is an urgent need for treatment optimization. Methods We selected C-type lectin domain family 11, member A (CLEC11A) for study via several public databases, comparing expression among a variety of tumors and normal samples as well as different organs and tissues. To investigated the relationship between CLEC11A expression and clinical characteristics, we derived an AML cohort from The Cancer Genome Atlas (TCGA); we also investigated the Bloodspot and HemaExplorer databases. The Kaplan-Meier method and log-rank test were used to evaluate the associations between CLEC11A mRNA expression, as well as DNA methylation, and overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS). DNA methylation levels of CLEC11A from our own 28 de novo AML patients were assessed and related to chemotherapeutic outcomes. Bioinformatics analysis of CLEC11A was carried out using public databases. Results Multiple public databases revealed that CLEC11A expression was higher in leukemia. The TCGA data revealed that high CLEC11A expression was linked with favorable prognosis (OS p -value = 2e-04; EFS p -value = 6e-04), which was validated in GSE6891 (OS p -value = 0; EFS p -value = 0; RFS p -value = 2e-03). Methylation of CLEC11A was negatively associated with CLEC11A expression, and high CLEC11A methylation level group was linked to poorer prognosis (OS p -value = 1e-02; EFS p -value = 2e-02). Meanwhile, CLEC11A hypermethylation was associated with poor induction remission rate and dismal survival. Bioinformatic analysis also showed that CLEC11A was an up-regulated gene in leukemogenesis. Conclusion CLEC11A may be used as a prognostic biomarker, and could do benefit for AML patients by providing precise treatment indications, and its unique gene pattern should aid in further understanding the heterogeneous AML mechanisms.

oncology
Identification of Potential Novel Prognosis-Related Genes Through Transcriptome Sequencing, Bioinformatics Analysis, and Clinical Validation in Acute Myeloid Leukemia

Jie Wang,Jian-ping Hao,Rong Chen,Yun-xia Xiang,Dai-qin Xiong,Yun Wu,Md. Nazim Uddin

DOI: https://doi.org/10.3389/fgene.2021.723001

IF: 3.7

2021-10-29

Frontiers in Genetics

Abstract:Background: Acute Myeloid Leukemia (AML) is a complex and heterogeneous hematologic malignancy. However, the function of prognosis-related signature genes in AML remains unclear. Methods: In the current study, transcriptome sequencing was performed on 15 clinical samples, differentially expressed RNAs were identified using R software. The potential interactions network was constructed by using the common genes between target genes of differentially expressed miRNAs with transcriptome sequencing results. Functional and pathway enrichment analysis was performed to identify candidate gene-mediated aberrant signaling pathways. Hub genes were identified by the cytohubba plugin in Cytoscape software, which then expanded the potential interactions regulatory module for hub genes. TCGA-LAML clinical data were used for the prognostic analysis of the hub genes in the regulatory network, and GVSA analysis was used to identify the immune signature of prognosis-related hub genes. qRT-PCR was used to verify the expression of hub genes in independent clinical samples. Results: We obtained 1,610 differentially expressed lncRNAs, 233 differentially expressed miRNAs, and 2,217 differentially expressed mRNAs from transcriptome sequencing. The potential interactions network is constructed by 12 lncRNAs, 25 miRNAs, and 692 mRNAs. Subsequently, a sub-network including 15 miRNAs as well as 12 lncRNAs was created based on the expanded regulatory modules of 25 key genes. The prognostic analysis results show that CCL5 and lncRNA UCA1 was a significant impact on the prognosis of AML. Besides, we found three potential interactions networks such as lncRNA UCA1 /hsa-miR-16-5p/ COL4A5 , lncRNA UCA1 /hsa-miR-16-5p/ SPARC , and lncRNA SNORA27 /hsa-miR-17-5p/ CCL5 may play an important role in AML. Furthermore, the evaluation of the immune infiltration shows that CCL5 is positively correlated with various immune signatures, and lncRNA UCA1 is negatively correlated with the immune signatures. Finally, the result of qRT-PCR showed that CCL5 is down-regulated and lncRNA UCA1 is up-regulated in AML samples separately. Conclusions: In conclusion, we propose that CCL5 and lncRNA UCA1 could be recognized biomarkers for predicting survival prognosis based on constructing competing endogenous RNAs in AML, which will provide us novel insight into developing novel prognostic, diagnostic, and therapeutic for AML.

genetics & heredity
Seroprevalence of Bartonella henselae and Bartonella quintana infections in children from Central and Northern Jordan.

A. Al-Majali,K. Al-Qudah

2004-11-01

Saudi Medical Journal

Abstract:OBJECTIVE To investigate the prevalence of antibodies to Bartonella henselae (B.henselae) and Bartonella quintana (B.quintana) among children from central and northern Jordan. METHODS Sera from 482 children were randomly collected from referenced governmental hospitals in the central and northern parts of Jordan during the period between January 2001 to March 2003. An indirect immunofluorescent assay was used to determine serum antibody titers to B.henselae and B.quintana. Sera that were reactive at a dilution >/-1:64 were considered positive. In addition, blood from 20 cats belonged to children with high B.henselae titers were tested using polymerase chain reaction. RESULTS Out of the 482 serum samples examined, 53 (11%) and 20 (4.1%) had positive antibody titers for B. henselae and B.quintana. Bartonella henselae was isolated from 4 cats that belonged to 3 children with high antibody titers to B.henselae-IgG. The seroprevalence of IgG antibodies to B.henselae was significantly higher (P<0.05) in children aged 7-10-years than in younger or older ones. Having a cat in the household and having a history of cat scratches or bites were strongly associated (P<0.01) with seropositivity to B.henselae-specific IgG. Cats ownership and history of cat scratches or bites had no impact on the prevalence of B.quintana. Seropositivity to B.henselae-specific IgG was significantly higher (P<0.01) in children from northern Jordan than in children from central Jordan. CONCLUSION This study substantiates the presence of B.henselae in Jordan, documents the seroreactivity to 2 Bartonella antigens, and suggests that cat ownership and history of cat scratches or bites are important epidemiological risk factors for B.henselae infection in Jordan.
LINC00649 underexpression is an adverse prognostic marker in acute myeloid leukemia

Chao Guo,Ya-yue Gao,Qian-qian Ju,Chun-xia Zhang,Ming Gong,Zhen-ling Li

DOI: https://doi.org/10.1186/s12885-020-07331-0

IF: 4.638

2020-09-03

BMC Cancer

Abstract:Abstract Background Long noncoding RNAs (lncRNA) play a role in leukemogenesis, maintenance, development, and therapeutic resistance of AML. While few studies have focused on the prognostic significance of LINC00649 in AML, which we aim to investigate in this present study. Methods We compared the expression level of LINC00649 between AML patients and healthy controls. The Kaplan-Meier curves of AML patients expressing high versus low level of LINC00649 was performed. The LINC00649 correlated genes/miRNAs/lncRNAs and methylation CpG sites were screened by Pearson correlation analysis with R (version 3.6.0), using TCGA-LAML database. The LINC00649 associated ceRNA network was established using lncBase 2.0 and miRWalk 2.0 online tools, combining results from correlation analysis. Finally, a prediction model was constructed using LASSO-Cox regression. Results LINC00649 was underexpressed in bone marrow of AML group than that in healthy control group. The patients of LINC00649-low group have significantly inferior PFS and OS. A total of 154 mRNAs, 31 miRNAs, 28 lncRNAs and 1590 methylated CpG sites were identified to be significantly correlated with LINC00649. Furthermore, the network of ceRNA was established with 6 miRNAs and 122 mRNAs. The Lasso-Cox model fitted OS/PFS to novel prediction models, which integrated clinical factors, ELN risk stratification, mRNA/miRNA expression and methylation profiles. The analysis of time-dependent ROC for our model showed a superior AUC (AUC = 0.916 at 1 year, AUC = 0.916 at 3 years, and AUC = 0.891 at 5 years). Conclusions Low expression of LINC00649 is a potential unfavorable prognostic marker for AML patients, which requires the further validation. The analysis by LASSO-COX regression identified a novel comprehensive model with a superior diagnostic utility, which integrated clinical and genetic variables.

oncology
Expression and Diagnostic Value of lncRNA BLACAT1 in Peripheral Blood of Patients with Acute Myeloid Leukemia

Xinglong Wu,Jiayin Wang,Dandan Li,Zhilong Xu

DOI: https://doi.org/10.7754/Clin.Lab.2019.190802

IF: 1.053

2020-01-01

Clinical Laboratory

Abstract:Background: The current study aims to investigate the expression of lncRNA BLACAT1 in patients with acute myeloid leukemia (AML) and to analyze its correlation with clinical prognosis. Methods: Peripheral blood samples were collected from 68 AML patients, including 48 patients with acute myeloid leukemia (AML), 20 patients with complete response (CR), and 30 patients with iron deficiency anemia (control group). LncRNA BLACAT1 was detected by real-time fluorescence quantitative PCR (qRT-PCR). The expression of BLACAT1 and its relationship with clinicopathological characteristics and prognosis were analyzed. Results: The expression of lncRNA BLACAT1 in AML patients was significantly higher than that in complete remission patients and iron deficiency anemia patients, but the expression of lncRNA BLACAT1 in AML-CR group and control group had no significant difference. Further study showed that the expression of lncRNA BLACAT1 was correlated with the National Comprehensive Cancer Network (NCCN) risk classification, the amount of platelet and bone marrow primordial cells (%), and survival status of patients. The median overall survival time of patients with high expression of lncRNA BLACAT1 was significantly shorter than those with low expression of lncRNA BLACAT1 (p < 0.05). Conclusions: LncRNA BLACAT1 was involved in regulating the occurrence and development of AML and can be used as a potential prognostic marker and therapeutic target for AML patients.
Clinical relevance of long non-coding RNA in acute myeloid leukemia: A systematic review with meta-analysis

Priya,Manoj Garg,Rashmi Talwar,Mohit Bharadwaj,Munindra Ruwali,Amit Kumar Pandey

DOI: https://doi.org/10.1016/j.leukres.2024.107595

2024-09-23

Abstract:Background: Long noncoding RNAs (lncRNAs) may function as prognostic biomarkers in acute myeloid leukaemia (AML). However, it is still unknown exactly how significant lncRNAs are for the prognosis of AML. With a focus on their prognostic and therapeutic potential, the study aimed to provide a comprehensive review of the literature regarding the role of lncRNAs in AML. Method: Pub Med, The Cochrane Library, Embase, Science Direct, Web of science, Scopus, and Google scholar were searched until November, 2023. Original publications of any type exploring the prognostic and therapeutic potential of lncRNAs in AML patients were included. Heterogeneity and publication bias were examined using the I2 test and a funnel plot, respectively. To quantify the relationship between various lncRNA expression in AML patient survival, odds ratios (ORs) or hazards ratios (HRs) with 95 % confidence intervals (CIs) were pooled. Quality of studies was assessed using the Critical Appraisal Checklists for Studies created by the Joanna Briggs Institute (JBI). Results: Twenty-seven studies including 5665 subjects were selected for the final analysis. In patients with AML, abnormal lncRNA expression has been associated with significant worse overall survival (pooled HR = 2.05, 95 % CI = 1.79-2.30, P <0.001), shorter disease-free survival (pooled HR = 2.17, 95 % CI = 1.13-3.22, P< 0.001), and lower complete remission rate (pooled HR = 0.27, 95 % CI = 0.11-0.43, P< 0.001). Poor prognoses have been attributed to increased expression of HOX transcript antisense intergenic RNA (HOTAIR), Promoter Of CDKN1A Antisense DNA Damage Activated RNA (PANDAR), Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1), RP11-222K16.2, Taurine Upregulated Gene 1 (TUG1), Small Nucleolar RNA Host Gene 5 (SNHG5), Growth Arrest Specific 5 (GAS5), and H19 and decreased expression of IGF1R Antisense Imprinted Non-Protein Coding RNA (IRAIN). Conclusion: The prognoses of AML patients are significantly associated with abnormally expressed lncRNAs, which may be used as prognostic indicators for predicting the patient outcomes.
Upregulation of Lncrna CCAT2 Predicts Poor Prognosis in Patients with Acute Myeloid Leukemia and is Correlated with Leukemic Cell Proliferation.

Jia-Jia Li,Jun-Feng Zhu,Feng Zhang,Ping-Ping Zhang,Jing-Jing Zhang

2018-01-01

Abstract:Increasing data have shown that the dysregulation of long non-coding RNAs (lncRNAs) is associated with a variety of human cancers, including acute myeloid leukemia (AML). Colon cancer-associated transcript-2 (CCAT2) gene encodes an lncRNA CCAT2 whose over-activation was observed in many human solid tumors. However the expression and clinical significance of CCAT2 in AML have not been identified. In the study, we found that CCAT2 expression levels in patients with AML were significantly increased compared with healthy individuals. The patients with highly expressed CCAT2 had higher white blood cells than those patients with low CCAT2. The incidence of FLT3/ITD mutation in the patients with high CCAT2 expression was significantly higher than in those patients with low CCAT2 expression. High CCAT2 expression was correlated with more monosomal karyotype and poor risk stratification. Furthermore, patients with high CCAT2 had significantly shorter overall survival times than those patients with low CCAT2. Univariate and multivariate Cox's analyses indicated a poor prognostic value of high CCAT2 in AML patients. Moreover, in vitro assay revealed that overexpression of CCAT2 promoted KG-1 cell proliferation and induced cell cycle arrest at the S phase, whereas CCAT2 knockdown inhibited proliferation by inducing cell-cycle arrest at the G2/M phase. In conclusion, our study demonstrates for the first time that CCAT2 is highly expressed in AML patients, and it associates with poor prognosis and leukemic cell proliferation.
Clinical and prognostic relevance of CXCL12 expression in acute myeloid leukemia

Shi-Sen Wang,Zi-Jun Xu,Ye Jin,Ji-Chun Ma,Pei-Hui Xia,Xiangmei Wen,Zhen-Wei Mao,Jiang Lin,Jun Qian

DOI: https://doi.org/10.7717/peerj.11820

IF: 3.061

2021-07-20

PeerJ

Abstract:Background: Accumulating studies have been made to understand the association between CXC chemokine ligand-12 (CXCL12)/CXC chemokine receptor 4 (CXCR4) and acute myeloid leukemia (AML). However, large-scale data analysis of potential relationship between CXCL12 and AML remains insufficient. Methods: We collected abundant CXCL12 expression data and AML samples from several publicly available datasets. The CIBERSORT algorithm was used to quantify immune cell fractions and the online website of STRING was utilized for gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. The statistical analysis and graphical work were mainly performed via the R software. Results: CXCL12 expression was extremely down-regulated in AML. Clinically, low CXCL12 expression was correlated with higher white blood cells (WBCs) (P < 0.0001), more blasts in bone marrow (BM) (P < 0.001) and peripheral blood (PB) (P < 0.0001), FLT3-internal tandem duplications (FLT3-ITD) (P = 0.010) and NPM1 mutations (P = 0.015). More importantly, reduced CXCL12 expression predicted worse overall survival (OS) and event-free survival (EFS) in all AML, non-M3-AML, and cytogenetically normal (CN)-AML patients in three independent cohorts. As for immune cell infiltration, high CXCL12 expressed groups tended to harbor more memory B cells and plasma cells infiltration while low CXCL12 expressed groups exhibited more eosinophils infiltration. GO enrichment and KEGG pathways analysis revealed the potential biological progress the gene participating in. Conclusions: CXCL12 is significantly down-regulated in AML and low CXCL12 expression is an independent and poor predictor of AML prognosis. CXCL12 expression level correlates with clinical and immune characteristics of AML, which could provide potential assistance for treatment. Prospective studies are needed to further validate the impact of CXCL12 expression before routine clinical application in AML.

Growth of nervous tissue in the regenerated rabbit ear chamber.

Prognostic Significance of Huntingtin Interacting Protein 1 Expression on Patients with Acute Myeloid Leukemia

Expression and Clinical Significance of ID1 Gene in Acute Myeloid Leukemia

Expression Characteristics and Prognosissignificance of Mirna-181A in Acute Myeloid Leukemia with Normal Karyotype

Prognostic Impact of MYH9 Expression on Patients with Acute Myeloid Leukemia

High IDH1 Expression is Associated with a Poor Prognosis in Cytogenetically Normal Acute Myeloid Leukemia.

Plasma exosome-derived microRNA-532 as a novel predictor for acute myeloid leukemia

Expression of BCL2L12 gene in de novo acute myeloid leukemia and its clinical implications]

The Expression of LEF1 Gene and Its Clinical Significance in Chinese Patients with Acute Myeloid Leukemia

Clinical significance of lymphoid enhancer-binding factor 1 expression in acute myeloid leukemia

[Expression of lncRNA UCA1 in Acute Myeloid Leukemia Patients and Its Clinical Significance]

High Expression of lncRNA HEIH is Helpful in the Diagnosis of Non-Small Cell Lung Cancer and Predicts Poor Prognosis

[New Advane of Reaserch on Relationship between Long Noncoding RNA and Acute Myeloid Leukemia--Review]

High Expression of CLEC11A Predicts Favorable Prognosis in Acute Myeloid Leukemia

Identification of Potential Novel Prognosis-Related Genes Through Transcriptome Sequencing, Bioinformatics Analysis, and Clinical Validation in Acute Myeloid Leukemia

Seroprevalence of Bartonella henselae and Bartonella quintana infections in children from Central and Northern Jordan.

LINC00649 underexpression is an adverse prognostic marker in acute myeloid leukemia

Expression and Diagnostic Value of lncRNA BLACAT1 in Peripheral Blood of Patients with Acute Myeloid Leukemia

Clinical relevance of long non-coding RNA in acute myeloid leukemia: A systematic review with meta-analysis

Upregulation of Lncrna CCAT2 Predicts Poor Prognosis in Patients with Acute Myeloid Leukemia and is Correlated with Leukemic Cell Proliferation.

Clinical and prognostic relevance of CXCL12 expression in acute myeloid leukemia